{"product_id":"abbv-business-model-canvas","title":"AbbVie Inc. (ABBV): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas of AbbVie Inc. gives you a practical, research-based view of how the company creates, delivers, and captures value through immunology, oncology, neuroscience, aesthetics, and eye care. You'll see the core drivers behind \u003cstrong\u003e90 active clinical programs\u003c\/strong\u003e and \u003cstrong\u003e55,000 employees\u003c\/strong\u003e, plus the roles of Skyrizi, Rinvoq, Botox, and Venclexta, key partnerships with Gilgamesh Pharmaceutical and RemeGen, payer and specialty pharmacy channels, major customer segments, revenue streams, and the main cost pressures from R\u0026amp;D, manufacturing, SG\u0026amp;A, and compliance.\u003c\/p\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2024 net revenues were $56,334 million.\u003c\/strong\u003e AbbVie Inc. depends on a small number of outside partners for pipeline development, manufacturing, distribution, and access, so each partnership lane has direct revenue and cash flow impact.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership area\u003c\/th\u003e\n\u003cth\u003eReal-life data\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilgamesh Pharmaceuticals, Inc.\u003c\/td\u003e\n\u003ctd\u003e1 neuroscience collaboration\u003c\/td\u003e\n\u003ctd\u003eExternal R\u0026amp;D in neuroplastogens\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemeGen Co., Ltd.\u003c\/td\u003e\n\u003ctd\u003e1 antibody-drug conjugate (ADC) development partnership\u003c\/td\u003e\n\u003ctd\u003eExternal oncology pipeline expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. wholesale distribution\u003c\/td\u003e\n\u003ctd\u003e3 major wholesalers\u003c\/td\u003e\n\u003ctd\u003ePrimary U.S. product flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy access\u003c\/td\u003e\n\u003ctd\u003e3 named channels\u003c\/td\u003e\n\u003ctd\u003eSpecialty-drug dispensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare and payer systems\u003c\/td\u003e\n\u003ctd\u003e10 drugs in the first Medicare price-negotiation cycle; $2,000 Part D out-of-pocket cap in 2025\u003c\/td\u003e\n\u003ctd\u003ePricing and patient access pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eGilgamesh Pharmaceuticals, Inc. gives AbbVie Inc. 1 external neuroscience partner in a field where trial failure is common. Neuroplastogens are compounds designed to increase neuroplasticity, which is the brain's ability to form new connections. For AbbVie Inc., that kind of collaboration matters because it adds outside discovery capacity without building every program internally.\u003c\/p\u003e\n\n\u003cp\u003eRemeGen Co., Ltd. gives AbbVie Inc. 1 external ADC development link. An antibody-drug conjugate (ADC) is a targeted cancer drug that combines an antibody with a cell-killing payload. The partnership expands AbbVie Inc.'s oncology options and reduces the need to fund every target and payload combination from scratch.\u003c\/p\u003e\n\n\u003cp\u003eAbbVie Inc.'s contract manufacturing model relies on outside capacity for drug substance, fill-finish, packaging, and testing. AbbVie Inc. does not disclose a full public count of those partners. That still matters because biologic production is harder to replace than tablet manufacturing, and a single-site delay can affect supply, launch timing, and inventory.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eDrug substance\u003c\/li\u003e\n\u003cli\u003eFill-finish\u003c\/li\u003e\n\u003cli\u003ePackaging\u003c\/li\u003e\n\u003cli\u003eQuality testing\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAbbVie Inc.'s healthcare-provider and specialty-pharmacy network is the access layer between the company and patients. In the U.S., product flow is concentrated through 3 major wholesalers: McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc. For selected specialty medicines, 3 common pharmacy channels are CVS Specialty, Accredo, and Optum Specialty. This matters because specialty drugs often need prior authorization, benefit verification, and controlled distribution.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMcKesson Corporation\u003c\/li\u003e\n\u003cli\u003eCencora, Inc.\u003c\/li\u003e\n\u003cli\u003eCardinal Health, Inc.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cul\u003e\n\u003cli\u003eCVS Specialty\u003c\/li\u003e\n\u003cli\u003eAccredo\u003c\/li\u003e\n\u003cli\u003eOptum Specialty\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAbbVie Inc.'s payer relationships are shaped by Medicare pricing rules. Humira was 1 of the 10 drugs selected for the first Medicare price-negotiation cycle, and the 2025 Medicare Part D out-of-pocket cap is \u003cstrong\u003e$2,000\u003c\/strong\u003e. That combination matters because specialty-drug access is no longer driven only by physician demand; it is also driven by plan design, patient cost-sharing, and federal pricing pressure.\u003c\/p\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003eAbbVie's key activities are research-heavy and deal-heavy. In 2023, it spent \u003cstrong\u003e$7.126 billion\u003c\/strong\u003e on R\u0026amp;D, equal to \u003cstrong\u003e13.1%\u003c\/strong\u003e of \u003cstrong\u003e$54.318 billion\u003c\/strong\u003e in net revenues, and expanded the pipeline with transactions worth \u003cstrong\u003e$63 billion\u003c\/strong\u003e, \u003cstrong\u003e$10.1 billion\u003c\/strong\u003e, and \u003cstrong\u003e$8.7 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eDrug discovery and clinical development\u003c\/p\u003e\n\u003cp\u003eAbbVie funds target identification, preclinical work, and human studies through \u003cstrong\u003ePhase 1\u003c\/strong\u003e, \u003cstrong\u003ePhase 2\u003c\/strong\u003e, and \u003cstrong\u003ePhase 3\u003c\/strong\u003e trials. The company's \u003cstrong\u003e$7.126 billion\u003c\/strong\u003e R\u0026amp;D budget in 2023 is the clearest sign that the business depends on continuous replacement of mature products with new clinical assets. At that spend level, R\u0026amp;D absorbed \u003cstrong\u003e13.1%\u003c\/strong\u003e of revenue. That ratio matters because it shows how much of each sales dollar is being pushed back into the pipeline instead of short-term profit.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.126 billion\u003c\/strong\u003e R\u0026amp;D expense in 2023\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e13.1%\u003c\/strong\u003e of 2023 net revenues spent on R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e main development stages: Phase 1, Phase 2, Phase 3\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegulatory filings and approvals\u003c\/p\u003e\n\u003cp\u003eAbbVie's regulatory activity turns trial data into filings, approvals, and label expansions. The main U.S. filing routes are \u003cstrong\u003e2\u003c\/strong\u003e: NDA and BLA. This work matters because an approval can convert years of trial spending into a longer revenue stream, while a label expansion can extend sales without needing a new molecule. In AbbVie's model, regulatory execution protects the value created by the \u003cstrong\u003e$7.126 billion\u003c\/strong\u003e annual R\u0026amp;D engine and helps offset pressure from product aging and biosimilar competition.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e main U.S. filing paths: NDA and BLA\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e trial phases before filing: Phase 1, Phase 2, Phase 3\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.126 billion\u003c\/strong\u003e in R\u0026amp;D creates the filing pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eGlobal manufacturing and supply chain management\u003c\/p\u003e\n\u003cp\u003eAbbVie's manufacturing and supply chain work has to support a revenue base of \u003cstrong\u003e$54.318 billion\u003c\/strong\u003e. If supply were disrupted by just \u003cstrong\u003e1%\u003c\/strong\u003e, the implied annual revenue exposure would be about \u003cstrong\u003e$543.2 million\u003c\/strong\u003e. That is why production planning, quality control, packaging, inventory management, and distribution are core activities rather than support tasks. The scale of the revenue base makes continuity and compliance financially important.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$54.318 billion\u003c\/strong\u003e 2023 net revenues to supply\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1%\u003c\/strong\u003e disruption equals about \u003cstrong\u003e$543.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e operational priorities: quality, continuity, distribution\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 net revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54.318 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eScale that supply must support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 R\u0026amp;D expense\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.126 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunding base for clinical development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D as a share of revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash committed to pipeline building\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1% of revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$543.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExposure from a small supply disruption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eCommercialization and lifecycle management\u003c\/p\u003e\n\u003cp\u003eAbbVie's commercialization work is built around extending the life of each product through new indications, new geographies, and new formulations. That matters because the company generated \u003cstrong\u003e$54.318 billion\u003c\/strong\u003e of net revenues in 2023 and had to keep that base moving after Humira lost U.S. exclusivity in \u003cstrong\u003e2023\u003c\/strong\u003e. Lifecycle management is the activity that turns a single approved drug into a multi-year revenue platform. It also reduces dependence on one product cycle by spreading revenue across a larger portfolio.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$54.318 billion\u003c\/strong\u003e 2023 revenue base to defend and grow\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e U.S. exclusivity loss for Humira\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e economic goals: defend share and extend product life\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eM\u0026amp;A integration and pipeline expansion\u003c\/p\u003e\n\u003cp\u003eAbbVie uses acquisitions to add assets faster than internal R\u0026amp;D alone can do. The largest recent deals were \u003cstrong\u003e$63 billion\u003c\/strong\u003e for Allergan, \u003cstrong\u003e$10.1 billion\u003c\/strong\u003e for ImmunoGen, and \u003cstrong\u003e$8.7 billion\u003c\/strong\u003e for Cerevel. Combined, those transactions equal \u003cstrong\u003e$81.8 billion\u003c\/strong\u003e, which is about \u003cstrong\u003e1.5x\u003c\/strong\u003e AbbVie's \u003cstrong\u003e$54.318 billion\u003c\/strong\u003e 2023 revenue base. That scale shows that acquisition integration is a major operating activity, not a side project. AbbVie has to fold in clinical assets, manufacturing, regulatory files, and commercial rights while keeping the existing portfolio running.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$63 billion\u003c\/strong\u003e Allergan acquisition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.1 billion\u003c\/strong\u003e ImmunoGen acquisition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.7 billion\u003c\/strong\u003e Cerevel acquisition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$81.8 billion\u003c\/strong\u003e combined deal value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1.5x\u003c\/strong\u003e combined deal value versus \u003cstrong\u003e$54.318 billion\u003c\/strong\u003e 2023 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeal\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePipeline role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllergan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$63 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDiversification and scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunoGen\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOncology expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCerevel\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNeuroscience expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$81.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExternal pipeline build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e55,000\u003c\/strong\u003e employees, \u003cstrong\u003e90\u003c\/strong\u003e active clinical programs, and \u003cstrong\u003e4\u003c\/strong\u003e core brands shape AbbVie Inc.'s key resource base.\u003c\/p\u003e\n\u003cp\u003eThe branded portfolio in this chapter is \u003cstrong\u003eSkyrizi\u003c\/strong\u003e, \u003cstrong\u003eRinvoq\u003c\/strong\u003e, \u003cstrong\u003eBotox\u003c\/strong\u003e, and \u003cstrong\u003eVenclexta\u003c\/strong\u003e. These assets sit alongside the ARCH AI and data platform and a global manufacturing footprint.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eReal-life figure\u003c\/th\u003e\n\u003cth\u003eBusiness model role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkyrizi, Rinvoq, Botox, Venclexta\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e brands\u003c\/td\u003e\n\u003ctd\u003eCurrent commercial base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical programs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePipeline renewal and future revenue base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e55,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eResearch, manufacturing, regulatory, and commercial execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARCH AI and data platform\u003c\/td\u003e\n\u003ctd\u003e1 platform\u003c\/td\u003e\n\u003ctd\u003eData analysis and research support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal manufacturing footprint\u003c\/td\u003e\n\u003ctd\u003e1 global network\u003c\/td\u003e\n\u003ctd\u003eSupply continuity, scale, and product quality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eSkyrizi\u003c\/strong\u003e and \u003cstrong\u003eRinvoq\u003c\/strong\u003e are the largest growth-oriented commercial resources in the group of four. They matter because they support current revenue generation while reducing reliance on older products.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eBotox\u003c\/strong\u003e and \u003cstrong\u003eVenclexta\u003c\/strong\u003e add breadth to the portfolio. They matter because they spread commercial risk across therapeutic areas and support recurring demand from specialty markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e marketed brands in this chapter: Skyrizi, Rinvoq, Botox, Venclexta\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e90\u003c\/strong\u003e active clinical programs\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e55,000\u003c\/strong\u003e employees\u003c\/li\u003e\n\u003cli\u003eARCH AI and data platform\u003c\/li\u003e\n\u003cli\u003eGlobal manufacturing footprint\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe \u003cstrong\u003e90\u003c\/strong\u003e active clinical programs are the clearest pipeline resource in the canvas. They matter because they support future product launches, label expansion, and lifecycle management across multiple therapeutic areas.\u003c\/p\u003e\n\u003cp\u003eThe ARCH AI and data platform matters because it improves how data is organized, analyzed, and used in research decisions. The value is in faster target selection, better trial design, and more efficient use of development capital.\u003c\/p\u003e\n\u003cp\u003eThe global manufacturing footprint matters because it supports production, quality control, and supply reliability for complex pharmaceutical products. In a business with biologics and specialty medicines, manufacturing capacity is a strategic resource, not just an operating function.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e55,000\u003c\/strong\u003e employees matter because AbbVie Inc. needs large teams across clinical development, regulatory affairs, pharmacovigilance, manufacturing, and commercial operations. That headcount is a capacity resource and a coordination resource at the same time.\u003c\/p\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003eAbbVie Inc.'s value proposition is built around \u003cstrong\u003e$54.3 billion\u003c\/strong\u003e in 2023 net revenues, led by \u003cstrong\u003e$23.4 billion\u003c\/strong\u003e in immunology, \u003cstrong\u003e$8.2 billion\u003c\/strong\u003e in neuroscience, \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e in oncology, and \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e in aesthetics. The company sells specialty therapies where clinical differentiation, repeat prescribing, and patient access matter more than low price.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eValue proposition theme\u003c\/th\u003e\n\u003cth\u003eReal-life numbers\u003c\/th\u003e\n\u003cth\u003eBusiness meaning\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-growth innovative therapeutics\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$54.3 billion\u003c\/strong\u003e in 2023 net revenues; Skyrizi \u003cstrong\u003e$7.8 billion\u003c\/strong\u003e; Rinvoq \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e; Humira \u003cstrong\u003e$14.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePremium specialty drugs support cash flow and fund pipeline reinvestment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBroad immunology, oncology, neuroscience portfolio\u003c\/td\u003e\n\u003ctd\u003eImmunology \u003cstrong\u003e$23.4 billion\u003c\/strong\u003e; neuroscience \u003cstrong\u003e$8.2 billion\u003c\/strong\u003e; oncology \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e; combined \u003cstrong\u003e$37.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRevenue is spread across multiple large therapy areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAesthetics and eye care solutions\u003c\/td\u003e\n\u003ctd\u003eAesthetics revenue \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e in 2023\u003c\/td\u003e\n\u003ctd\u003eCreates a second demand engine beyond prescription pharmaceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrong clinical efficacy and new indications\u003c\/td\u003e\n\u003ctd\u003eMultiple disease areas, including Crohn's disease, ulcerative colitis, psoriatic arthritis, atopic dermatitis, lymphoma, and multiple myeloma\u003c\/td\u003e\n\u003ctd\u003eMore approved uses expand the eligible patient pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient access support through myAbbVie Assist\u003c\/td\u003e\n\u003ctd\u003eEligible U.S. patients can obtain medicine at no cost\u003c\/td\u003e\n\u003ctd\u003eReduces access friction in specialty prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHigh-growth innovative therapeutics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbVie Inc. uses high-growth therapies to offset mature product pressure and keep the revenue base moving. In 2023, Skyrizi generated \u003cstrong\u003e$7.8 billion\u003c\/strong\u003e, Rinvoq generated \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e, and Humira still generated \u003cstrong\u003e$14.4 billion\u003c\/strong\u003e. That mix shows the core value proposition: one legacy blockbuster can still throw off scale, while newer immunology drugs carry the growth case. Immunology alone delivered \u003cstrong\u003e43%\u003c\/strong\u003e of 2023 net revenues, which is why this franchise matters to both growth and margin stability.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSkyrizi: \u003cstrong\u003e$7.8 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRinvoq: \u003cstrong\u003e$5.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHumira: \u003cstrong\u003e$14.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eImmunology share of total revenue: \u003cstrong\u003e43%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBroad immunology, oncology, neuroscience portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbVie Inc. does not rely on one therapeutic area. Immunology, neuroscience, and oncology generated \u003cstrong\u003e$37.2 billion\u003c\/strong\u003e in 2023, which was \u003cstrong\u003e68%\u003c\/strong\u003e of total company revenue when you use the disclosed segment totals. That spread matters because it lowers dependence on any single patent cliff or reimbursement cycle. It also gives the company more than one path to growth when one franchise slows.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eImmunology: \u003cstrong\u003e$23.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNeuroscience: \u003cstrong\u003e$8.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOncology: \u003cstrong\u003e$5.6 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCombined: \u003cstrong\u003e$37.2 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCombined share of total revenue: \u003cstrong\u003e68%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eImmunology includes Humira, Skyrizi, and Rinvoq. Oncology includes Imbruvica, Venclexta, Epkinly, and Elahere. Neuroscience includes Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta. That lineup matters because each product serves a different prescriber base, so AbbVie Inc. can diversify demand across rheumatology, gastroenterology, oncology, neurology, and psychiatry.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAesthetics and eye care solutions\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbVie Inc.'s aesthetics business gave it \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e in 2023 revenue. This is a different kind of value proposition from prescription medicine because demand is tied more to elective consumer spending and procedural visits than to chronic disease management. That creates a separate cash flow stream with different drivers from immunology or oncology. Eye care solutions add breadth to the specialty portfolio, even when they are not as large as the flagship drug franchises.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eAesthetics revenue: \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eRevenue source: elective and specialist-driven demand\u003c\/li\u003e\n\u003cli\u003ePortfolio role: non-pharma balance to prescription therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrong clinical efficacy and new indications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAbbVie Inc. wins value when one drug proves useful across several diseases. That matters because each additional indication expands the eligible patient pool and can lengthen the commercial life of the asset. The company's immunology portfolio spans Crohn's disease, ulcerative colitis, psoriatic arthritis, and atopic dermatitis. Its oncology portfolio spans lymphoma and multiple myeloma. More approved uses also make the drugs harder to replace, because prescribers can build habit and experience around therapies that show consistent clinical results across settings.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eCrohn's disease\u003c\/li\u003e\n\u003cli\u003eulcerative colitis\u003c\/li\u003e\n\u003cli\u003epsoriatic arthritis\u003c\/li\u003e\n\u003cli\u003eatopic dermatitis\u003c\/li\u003e\n\u003cli\u003elymphoma\u003c\/li\u003e\n\u003cli\u003emultiple myeloma\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient access support through myAbbVie Assist\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003emyAbbVie Assist supports eligible U.S. patients by providing medicine at no cost. That matters in specialty care because prior authorization, copays, and insurance denials can block treatment even when a drug is clinically appropriate. Access support helps reduce therapy abandonment and can improve persistence on treatment, which strengthens the commercial value of the drug portfolio.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEligible U.S. patients\u003c\/li\u003e\n\u003cli\u003eMedicine at no cost\u003c\/li\u003e\n\u003cli\u003eSpecialty-drug access support\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eAbbVie Inc. builds customer relationships around physicians, payers, and repeat patients, and that matters in a business that produced \u003cstrong\u003e$54.3B\u003c\/strong\u003e in net revenues in \u003cstrong\u003e2023\u003c\/strong\u003e while U.S. Humira biosimilar competition began on \u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRelationship channel\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMain customer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life data point\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eBusiness impact\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician-led specialty care support\u003c\/td\u003e\n\u003ctd\u003eDermatologists, rheumatologists, gastroenterologists, neurologists\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$54.3B\u003c\/strong\u003e net revenues in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEach specialist account can drive recurring prescriptions over months or years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient assistance and affordability programs\u003c\/td\u003e\n\u003ctd\u003eCommercially insured, uninsured, and underinsured patients\u003c\/td\u003e\n\u003ctd\u003eHumira U.S. biosimilar competition began on \u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAffordability, switching, and refill persistence became more important\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand loyalty programs like Allē\u003c\/td\u003e\n\u003ctd\u003eAesthetics patients and provider offices\u003c\/td\u003e\n\u003ctd\u003eAllē launched in \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eRepeat elective treatments depend on ongoing patient engagement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical education and field support\u003c\/td\u003e\n\u003ctd\u003eHealth care professionals\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEducation reduces friction for diagnosis, onboarding, and therapy persistence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term payer contracting\u003c\/td\u003e\n\u003ctd\u003ePBMs, commercial plans, and government payers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFormulary access and rebates affect net revenue and volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhysician-led specialty care support.\u003c\/strong\u003e AbbVie Inc. depends on specialists because its medicines are usually started, monitored, and renewed by physicians rather than bought directly by patients. In \u003cstrong\u003e2023\u003c\/strong\u003e, the company's \u003cstrong\u003e$54.3B\u003c\/strong\u003e revenue base made every prior authorization, refill, and follow-up visit financially important. The relationship is strongest when AbbVie Inc. gives doctors dosing guidance, administration support, side-effect management information, and adherence tools. That reduces treatment drop-off and protects long-duration revenue in chronic disease categories.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$54.3B\u003c\/strong\u003e net revenues in \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSpecialist prescribing ties revenue to clinical follow-up.\u003c\/li\u003e\n\u003cli\u003eRefill continuity is more valuable than one-time prescribing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient assistance and affordability programs.\u003c\/strong\u003e AbbVie Inc. uses affordability support because high out-of-pocket costs can interrupt therapy. The start of U.S. Humira biosimilar competition on \u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e made price sensitivity, switching, and patient retention much more important. In practice, these programs can include copay support, benefits verification, and access help for eligible patients. The relationship matters because a patient who cannot afford the first refill is unlikely to become a long-term customer.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e is the key U.S. Humira competition date.\u003c\/li\u003e\n\u003cli\u003eAffordability affects first-fill and refill behavior.\u003c\/li\u003e\n\u003cli\u003eSupport programs protect persistence and access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBrand loyalty programs like Allē.\u003c\/strong\u003e Allē launched in \u003cstrong\u003e2020\u003c\/strong\u003e, and that date matters because aesthetics is a repeat-treatment business. Unlike reimbursed prescription drugs, aesthetic demand is often cash pay and cycle-driven, so loyalty tools help keep patients tied to provider offices. The relationship is built around repeat visits, rewards, and a smoother path from first treatment to the next one. That makes consumer retention a direct revenue lever, not just a marketing tool.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2020\u003c\/strong\u003e launch year for Allē.\u003c\/li\u003e\n\u003cli\u003eRepeat treatments drive the economics of aesthetics.\u003c\/li\u003e\n\u003cli\u003ePatient loyalty supports recurring office visits.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedical education and field support.\u003c\/strong\u003e AbbVie Inc. uses field teams, medical affairs staff, training materials, and congress activity to keep physicians engaged after launch. In \u003cstrong\u003e2023\u003c\/strong\u003e, this mattered because the company was managing a major portfolio shift after Humira exclusivity erosion. Medical education helps doctors understand dosing, safety, patient selection, and switching pathways. It also helps office staff handle prior authorizations and treatment onboarding, which affects whether the prescription actually gets filled.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e was a major transition year for AbbVie Inc.\u003c\/li\u003e\n\u003cli\u003eField support lowers prescribing friction.\u003c\/li\u003e\n\u003cli\u003eMedical education affects adoption and persistence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term payer contracting.\u003c\/strong\u003e Payer relationships sit at the center of AbbVie Inc.'s access model because insurers, PBMs, and government programs decide formulary placement, rebates, and coverage rules. Gross-to-net means the gap between list price and net revenue after rebates, discounts, and patient support. The U.S. Humira exclusivity break on \u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e showed why long-term contracts matter: access terms can change volume, net pricing, and patient switching all at once. For AbbVie Inc., payer contracting is not a back-office task; it is a core customer relationship that shapes revenue realization.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e marks the U.S. exclusivity break.\u003c\/li\u003e\n\u003cli\u003eFormulary access affects net revenue, not just unit sales.\u003c\/li\u003e\n\u003cli\u003eRebates and discounts are built into the customer relationship.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMetric\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer relationship relevance\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbbVie Inc. net revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54.3B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eShows the scale behind physician, payer, and patient retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Humira biosimilar competition start\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 31, 2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRaised the importance of affordability and payer access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAllē launch year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2020\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnchors the loyalty model in aesthetics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eAbbVie Inc. relies on a specialty-care channel structure. In 2024, the company reported \u003cstrong\u003e$56.334 billion\u003c\/strong\u003e in net revenues and about \u003cstrong\u003e55,000\u003c\/strong\u003e employees, which shows the scale needed to reach physicians, hospitals, pharmacies, and patients directly.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eHow it works\u003c\/td\u003e\n\u003ctd\u003eAbbVie Inc. channel relevance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty physicians and clinics\u003c\/td\u003e\n\u003ctd\u003eSpecialists diagnose, prescribe, monitor, and renew treatment for complex chronic and high-acuity conditions\u003c\/td\u003e\n\u003ctd\u003eThese prescribers are the main entry point for specialty medicines tied to AbbVie Inc.'s \u003cstrong\u003e$56.334 billion\u003c\/strong\u003e revenue base in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals and oncology centers\u003c\/td\u003e\n\u003ctd\u003eHospital accounts and cancer centers handle protocol-based initiation, infusion workflows, and multidisciplinary care\u003c\/td\u003e\n\u003ctd\u003eThese settings matter because access depends on institutional formulary decisions and treatment pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy networks\u003c\/td\u003e\n\u003ctd\u003eSpecialty pharmacies manage prior authorization, benefits verification, cold-chain handling, refill coordination, and adherence support\u003c\/td\u003e\n\u003ctd\u003eThis channel is critical when prescriptions need tight coordination rather than standard retail dispensing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect patient support programs\u003c\/td\u003e\n\u003ctd\u003ePatient services help with coverage, affordability, nurse support, education, and refill persistence\u003c\/td\u003e\n\u003ctd\u003eThese programs reduce abandonment after prescription and keep long-duration therapy moving through the channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal commercial sales force\u003c\/td\u003e\n\u003ctd\u003eField teams work with specialists, hospitals, payers, and pharmacies across markets\u003c\/td\u003e\n\u003ctd\u003eAbbVie Inc.'s about \u003cstrong\u003e55,000\u003c\/strong\u003e employees give it the operating base for market access, account management, and product education\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty physicians and clinics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is the most important channel because AbbVie Inc. sells medicines that usually start with a specialist diagnosis, not a walk-in retail purchase. Rheumatologists, dermatologists, gastroenterologists, neurologists, and oncologists control access through diagnosis, lab monitoring, and repeat prescribing. That makes the physician relationship part of the value chain, not just a sales step. For academic work, this channel shows why AbbVie Inc. depends on medical evidence, guideline adoption, and payer approval as much as on brand strength.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpecialists decide whether treatment starts.\u003c\/li\u003e\n\u003cli\u003eMonitoring requirements keep the physician involved after launch.\u003c\/li\u003e\n\u003cli\u003eRepeat prescriptions make retention as important as first access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospitals and oncology centers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHospital systems and oncology centers matter because they handle higher-acuity treatment, protocol-based care, and account-level access decisions. In these settings, the channel is shaped by formulary review, clinical pathways, and oncology service lines. That makes the buyer different from a retail pharmacy customer. For research and case study work, this channel shows how AbbVie Inc. sells into institutional decision-making, where reimbursement and care standards can matter as much as the drug itself.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eHospital formularies affect adoption.\u003c\/li\u003e\n\u003cli\u003eOncology centers influence protocol use.\u003c\/li\u003e\n\u003cli\u003eAccount access can be slower than retail access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialty pharmacy networks\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSpecialty pharmacy is a core channel for complex therapies because it manages benefits verification, prior authorization, shipment timing, and refill coordination. This matters for drugs that are expensive, tightly controlled, or linked to patient adherence programs. The channel also reduces friction between the prescriber and the patient by handling paper-heavy reimbursement steps. In financial terms, this channel helps protect realized revenue by lowering prescription drop-off after the physician writes the script.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrior authorization delays can block fills.\u003c\/li\u003e\n\u003cli\u003eBenefits verification affects whether the prescription becomes revenue.\u003c\/li\u003e\n\u003cli\u003eRefill management supports persistence on therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect patient support programs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePatient support programs are part of the channel because they keep prescriptions from failing after approval. They typically cover affordability, enrollment, education, nurse contact, and help with insurance paperwork. That matters in specialty medicine, where even a written prescription can stall if the patient cannot complete the reimbursement process. For academic writing, this channel is important because it connects commercial strategy with access, adherence, and real-world treatment continuation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCoverage support reduces abandonment.\u003c\/li\u003e\n\u003cli\u003eEducation improves persistence.\u003c\/li\u003e\n\u003cli\u003eAffordability tools can widen access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal commercial sales force\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA large commercial field organization is needed because AbbVie Inc. does not depend on mass retail alone. The company must cover specialists, hospitals, pharmacies, payers, and country-level market access rules across a global footprint. Its about \u003cstrong\u003e55,000\u003c\/strong\u003e employees support this model by giving it the scale to manage field promotion, medical education, reimbursement work, and account development. In business model terms, the sales force is the execution layer that connects the product portfolio to the right prescribers and institutions.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eField teams support specialist education.\u003c\/li\u003e\n\u003cli\u003eAccount managers work with hospital systems and payers.\u003c\/li\u003e\n\u003cli\u003eGlobal coverage helps move products through local reimbursement rules.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eImmunology patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCondition\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eGeography\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRheumatoid arthritis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePsoriasis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrohn's disease and ulcerative colitis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEczema\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eNet revenues\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkyrizi\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.71B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRinvoq\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.97B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumira\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.99B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.67B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRheumatoid arthritis: \u003cstrong\u003e1.3 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePsoriasis: \u003cstrong\u003e7.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCrohn's disease and ulcerative colitis: \u003cstrong\u003e3 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEczema: \u003cstrong\u003e31.6 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMeasure\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eGeography\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew cancer cases\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,001,140\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic lymphocytic leukemia and small lymphocytic lymphoma\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23,690\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute myeloid leukemia\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20,800\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew cancer cases: \u003cstrong\u003e2,001,140\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eChronic lymphocytic leukemia and small lymphocytic lymphoma: \u003cstrong\u003e23,690\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcute myeloid leukemia: \u003cstrong\u003e20,800\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eNeuroscience and migraine patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eMeasure\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eGeography\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigraine sufferers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e39 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMigraine sufferers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWorldwide\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic migraine sufferers\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. migraine sufferers: \u003cstrong\u003e39 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eWorldwide migraine sufferers: \u003cstrong\u003e1 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eU.S. chronic migraine sufferers: \u003cstrong\u003e4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAesthetics consumers\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProcedure\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eGeography\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimally invasive cosmetic procedures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBotulinum toxin type A procedures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHyaluronic acid filler procedures\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMinimally invasive cosmetic procedures: \u003cstrong\u003e25.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eBotulinum toxin type A procedures: \u003cstrong\u003e9.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHyaluronic acid filler procedures: \u003cstrong\u003e5.6 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eEye care patients and providers\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCondition\u003c\/th\u003e\n\u003cth\u003eNumber\u003c\/th\u003e\n\u003cth\u003eGeography\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry eye disease\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlaucoma\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCataract, age 40 and older\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eU.S.\u003c\/td\u003e\n\u003ctd\u003eLatest available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDry eye disease: \u003cstrong\u003e16 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGlaucoma: \u003cstrong\u003e4.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCataract, age 40 and older: \u003cstrong\u003e24.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$56.33B\u003c\/strong\u003e net revenues in 2024, with \u003cstrong\u003e$7.8B\u003c\/strong\u003e research and development, \u003cstrong\u003e$12.0B\u003c\/strong\u003e selling, general and administrative, \u003cstrong\u003e$15.1B\u003c\/strong\u003e cost of products sold, \u003cstrong\u003e$10.1B\u003c\/strong\u003e ImmunoGen, \u003cstrong\u003e$8.7B\u003c\/strong\u003e Cerevel, and \u003cstrong\u003e$2.37B\u003c\/strong\u003e opioid settlement exposure.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost structure item\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eYear or transaction\u003c\/td\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of products sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunoGen acquisition value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCerevel acquisition value\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid settlement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.37B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLegacy litigation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend: \u003cstrong\u003e$7.8B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eClinical trial-heavy pipeline investment: \u003cstrong\u003e13.8%\u003c\/strong\u003e of \u003cstrong\u003e$56.33B\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eSG\u0026amp;A and commercial force: \u003cstrong\u003e$12.0B\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eCommercial cost base: \u003cstrong\u003e21.3%\u003c\/strong\u003e of \u003cstrong\u003e$56.33B\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eManufacturing and supply cost: \u003cstrong\u003e$15.1B\u003c\/strong\u003e\n\u003c\/li\u003e\n \u003cli\u003eManufacturing cost base: \u003cstrong\u003e26.8%\u003c\/strong\u003e of \u003cstrong\u003e$56.33B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCategory\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of products sold\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunoGen\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCerevel\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.7B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid settlement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.37B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLegacy litigation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.8B\u003c\/strong\u003e R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$12.0B\u003c\/strong\u003e SG\u0026amp;A\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$15.1B\u003c\/strong\u003e cost of products sold\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$10.1B\u003c\/strong\u003e ImmunoGen\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.7B\u003c\/strong\u003e Cerevel\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.37B\u003c\/strong\u003e opioid settlement\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbbVie Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$56.3 billion\u003c\/strong\u003e, \u003cstrong\u003e$11.7 billion\u003c\/strong\u003e, \u003cstrong\u003e$6.0 billion\u003c\/strong\u003e, \u003cstrong\u003e$9.0 billion\u003c\/strong\u003e, \u003cstrong\u003e$2.9 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.6 billion\u003c\/strong\u003e, \u003cstrong\u003e$3.6 billion\u003c\/strong\u003e, \u003cstrong\u003e$2.5 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e, \u003cstrong\u003e$0.5 billion\u003c\/strong\u003e, \u003cstrong\u003e$0.5 billion\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 net revenues\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription drug sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$56.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSkyrizi\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRinvoq\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumira\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBotox Therapeutic\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBotox Cosmetic\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImbruvica\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVenclexta\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJuvederm Collection\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestasis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLumigan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePrescription drug sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003e$56.3 billion\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.0 billion\u003c\/strong\u003e Humira\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.7 billion\u003c\/strong\u003e Skyrizi\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.0 billion\u003c\/strong\u003e Rinvoq\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.6 billion\u003c\/strong\u003e Imbruvica\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.5 billion\u003c\/strong\u003e Venclexta\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSkyrizi and Rinvoq revenues\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.7 billion\u003c\/strong\u003e Skyrizi\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.0 billion\u003c\/strong\u003e Rinvoq\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$17.7 billion\u003c\/strong\u003e combined\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBotox Therapeutic and Botox Cosmetic sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.9 billion\u003c\/strong\u003e Botox Therapeutic\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.6 billion\u003c\/strong\u003e Botox Cosmetic\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.5 billion\u003c\/strong\u003e combined\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$3.6 billion\u003c\/strong\u003e Imbruvica\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.5 billion\u003c\/strong\u003e Venclexta\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.1 billion\u003c\/strong\u003e combined\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eEye care and aesthetics product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e Juvederm Collection\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$0.5 billion\u003c\/strong\u003e Restasis\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$0.5 billion\u003c\/strong\u003e Lumigan\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.6 billion\u003c\/strong\u003e Botox Cosmetic\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601580355733,"sku":"abbv-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/abbv-business-model-canvas.png?v=1740140861","url":"https:\/\/dcf-analysis.com\/products\/abbv-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}